Health Economics›Waldenstroem macroglobulinemia›First-line therapy

First-line therapy

Waldenstroem macroglobulinemia · 7 regimens

Cost estimates only — modelled on a typical patient (BSA 1.7 m², 70 kg, CrCl 90 mL/min) using the cheapest available formulary presentation. Excludes vial wastage, facility fees, supportive care, and infusion consumables. Not for billing, formulary decisions, or clinical use.

Filters

Y-axis

Cost vs Efficacy · 4 points

Fully pricedPartial pricing

Regimen	Biomarker	Cost/cycle ↓	Cycle	PFS ↕	OS ↕	Est. cycles	Course cost ↕	Evidence
Thalidomide and Rituximab Variant #01	—	R 152 755	28d	—	—	—	—	—
FCR Variant #09	—	R 70 417	28d	~56.4 mo	—	~62	~R 4 365 849 PFS proxy · indirect	10
Bortezomib and Rituximab (VR) Variant #06	—	R 64 235	35d	~12.8 mo	—	~12	~R 770 814 PFS proxy · indirect	1
R-CHOP Variant #23	—	R 59 865	21d	~44.4 mo	—	~65	~R 3 891 219 PFS proxy · indirect	4
Cladribine and Rituximab Variant #01	—	R 33 968	21d	—	—	—	—	—
Thioguanine monotherapy Variant #01	—	R 6 994	28d	—	—	—	—	—
Ofatumumab monotherapy N/A - secondary systemic drug	—	R 2	56d	~8.1 mo	—	~5	~R 9 PFS proxy · indirect	4

7 of 7 regimens shown